NVAX

Novavax Inc

Add to Watchlist

Advanced Chart

8.370

-0.41(-4.670%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

9.1278

Open

8.750

VWAP

8.51

Vol

9.98M

Mkt Cap

1.36B

Low

8.280

Amount

84.88M

EV/EBITDA(TTM)

2.56

Total Shares

147.30M

1.04B

EV/OCF(TTM)

P/S(TTM)

1.37

Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

136.00M

-79.6%

0.150

-94.88%

141.49M

+60.22%

-0.848

+63.08%

51.59M

-38.96%

-1.026

+35.04%

Estimates Revision

The market is revising Upward the revenue expectations for Novavax, Inc. (NVAX) for FY2025, with the revenue forecasts being adjusted by 6.74% over the past three months. During the same period, the stock price has changed by 40.08%.

Revenue Estimates for FY2025

Revise Upward

+6.74%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+19.79%

In Past 3 Month

Stock Price

Go Up

+40.08%

In Past 3 Month

5 Analyst Rating

21.86% Upside

Wall Street analysts forecast NVAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NVAX is 10.20 USD with a low forecast of 6.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

2 Hold

2 Sell

Hold

21.86% Upside

Current: 8.370

Low

6.00

Averages

10.20

High

19.00

21.86% Upside

Current: 8.370

Low

6.00

Averages

10.20

High

19.00

TD Cowen

Hold

downgrade

$9 -> $8

2025-08-04

New

Reason

TD Cowen

Price Target

$9 -> $8

2025-08-04

New

downgrade

Hold

Reason

TD Cowen lowered the firm's price target on Novavax to $8 from $9 and keeps a Hold rating on the shares. The firm updated the company's model post the Q2 results to reflect a 49% decrease in the number of U.S. adults eligible for COVID-19 boosters under a risk-based FDA label. TD believes positive results from Novavax's recently initiated Phase 4 Nuvaxovid efficacy trial could bring share uipside.

BofA

Alec Stranahan

Neutral

downgrade

$10 -> $9

2025-07-22

Reason

BofA

Alec Stranahan

Price Target

$10 -> $9

2025-07-22

downgrade

Neutral

Reason

BofA analyst Alec Stranahan lowered the firm's price target on Novavax to $9 from $10 and keeps a Neutral rating on the shares. The firm expects the predominate focus for the Q2 report and call will be on management guidance around the upcoming vaccine season, the analyst tells investors in an earnings preview for its small-to-mid cap biotech coverage.

Citi

Sell

initiated

2025-06-18

Reason

Citi

Price Target

2025-06-18

initiated

Sell

Reason

Citi initiated coverage of Novavax with a Sell rating and $6 price target. The firm acknowledges vaccines remain a "key cornerstone" to global health and that Novavax's technologies could contribute to the creation of innovative, new ones. However, the company's "overwhelming concentration" in respiratory vaccines, an area that is seeing a decline in vaccination rates and has many entrenched players, along with healthcare policies that are "in flux" and "not encouraging" towards vaccines, makes it challenging to establish a line of sight to success for Novavax, the analyst tells investors in a research note.

JPMorgan

Underweight

downgrade

$9 -> $7

2025-05-09

Reason

JPMorgan

Price Target

$9 -> $7

2025-05-09

downgrade

Underweight

Reason

JPMorgan lowered the firm's price target on Novavax to $7 from $9 and keeps an Underweight rating on the shares. The company's Q2 beat was driven by the accelerated recognition of deferred revenue, the analyst tells investors in a research note. However, the firm sees the "saga" surrounding the application for Novavax's COVID-19 vaccine dominating investor attention given eligible milestones from partner Sanofi. JPMorgan expects the shares to re-rate down on the "increasingly onerous vaccine regulatory environment."

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

$19

2024-12-10

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

$19

2024-12-10

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

$19

2024-11-13

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

$19

2024-11-13

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Novavax Inc (NVAX.O) is 9.18, compared to its 5-year average forward P/E of 0.82. For a more detailed relative valuation and DCF analysis to assess Novavax Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

0.82

Current PE

9.18

Overvalued PE

24.57

Undervalued PE

-22.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-13.14

Current EV/EBITDA

4.53

Overvalued EV/EBITDA

49.03

Undervalued EV/EBITDA

-75.32

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

2.50

Current PS

4.04

Overvalued PS

4.62

Undervalued PS

0.38